Bowhead Specialty (NYSE:BOW) Given New $33.00 Price Target at JMP Securities

Bowhead Specialty (NYSE:BOW) had its price target raised by stock analysts at JMP Securities from $32.00 to $33.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. JMP Securities’ target price points to a potential upside of 5.87% from the company’s previous close.

BOW has been the topic of a number of other reports. Keefe, Bruyette & Woods increased their price target on shares of Bowhead Specialty from $30.00 to $33.00 and gave the company a “market perform” rating in a research report on Tuesday, October 29th. Royal Bank of Canada increased their price target on shares of Bowhead Specialty from $32.00 to $35.00 and gave the company an “outperform” rating in a research report on Wednesday. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Bowhead Specialty presently has an average rating of “Hold” and an average price target of $30.80.

Bowhead Specialty Trading Up 4.6 %

NYSE:BOW traded up $1.37 on Wednesday, hitting $31.17. 126,986 shares of the stock were exchanged, compared to its average volume of 182,713. Bowhead Specialty has a 52 week low of $22.14 and a 52 week high of $32.55. The business has a 50-day moving average of $29.45.

Bowhead Specialty (NYSE:BOW) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.38 earnings per share for the quarter, hitting the consensus estimate of $0.38. The firm had revenue of $116.76 million for the quarter, compared to the consensus estimate of $113.00 million. As a group, equities analysts predict that Bowhead Specialty will post 1.3 EPS for the current year.

Insider Transactions at Bowhead Specialty

In other news, Director Family Mutual Insuran American sold 1,362,285 shares of the firm’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $27.70, for a total transaction of $37,735,294.50. Following the completion of the transaction, the director now directly owns 4,700,761 shares of the company’s stock, valued at $130,211,079.70. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Hedge Funds Weigh In On Bowhead Specialty

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Emerald Mutual Fund Advisers Trust grew its stake in shares of Bowhead Specialty by 0.5% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 194,333 shares of the company’s stock valued at $5,443,000 after buying an additional 937 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Bowhead Specialty in the second quarter valued at $117,000. Sandia Investment Management LP bought a new position in shares of Bowhead Specialty in the second quarter valued at $127,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Bowhead Specialty during the 2nd quarter valued at $192,000. Finally, Emerald Advisers LLC lifted its holdings in Bowhead Specialty by 3.3% during the 3rd quarter. Emerald Advisers LLC now owns 242,633 shares of the company’s stock valued at $6,796,000 after purchasing an additional 7,683 shares during the last quarter.

About Bowhead Specialty

Bowhead Specialty Holdings Inc provides specialty property and casualty insurance products in the United States. It underwrites casualty insurance solutions for risks in the construction, distribution, heavy manufacturing, real estate, and hospitality segments; professional liability insurance solutions for financial institutions, private and public directors and officers liability insurance, errors and omissions liability insurance, and cyber segments; and healthcare solutions for hospitals, senior care providers, managed care organizations, miscellaneous medical facilities, and healthcare management liability segments.